Fight for Vildagliptin: Natco goes to court against Novartis Farhat Nasim7 Sept 2019 4:32 PM ISTMumbai: Throwing an indirect challenge at patent holder Novartis, drugmaker Natco Pharma has submitted a fresh application in a Hyderabad court...
Roche touts drugs pipeline, rules out Merger and Acquisition just to boost sales Medical Dialogues Bureau7 Sept 2019 9:15 AM ISTRoche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for...
Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm Medical Dialogues Bureau5 Sept 2019 9:15 AM ISTZURICH: Novartis sees cell and gene therapies accounting for up to 15% of its total revenue in the midterm from a much lower level at present, a Swiss...
Lindsay Goldberg to buy Bilcare Research in a deal worth USD 279-334 million: Report Medical Dialogues Bureau5 Sept 2019 9:00 AM ISTBilcare Research, which employs 1000 staff and has annual sales of 300 million euros, produces plastic packaging used in the pharmaceutical, consumer...
Novartis, Lonza strengthen biosimilars push with MS, arthritis drug deals Medical Dialogues Bureau3 Sept 2019 9:30 AM ISTNovartis's Sandoz generics unit, among the biggest biosimilars makers, on Tuesday, agreed to license from Poland's Polpharma Biologics a version of...
Sanofi revival depends on outsider with nose for big drugs: Report Medical Dialogues Bureau3 Sept 2019 8:58 AM ISTDefining Sanofi's ambitions in the cutting-edge field of gene therapies and figuring out whether to hold on to consumer health brands are among other...
Delhi HC given Green Signal to Natco Pharma for generic of Novartis cancer drug Ceritinib Farhat Nasim1 Sept 2019 2:33 PM ISTNew Delhi: In a major relief to Natco, the Delhi High Court has lifted a ban on Natco Pharma from manufacturing fresh stock of on-small cell lung...
GSK Belantamab Mafodotin shows to help blood cancer patients Medical Dialogues Bureau26 Aug 2019 9:15 AM ISTTwo doses of Belantamab Mafodotin helped subdue the disease in adults who had received three prior treatments for multiple myeloma, a cancer of the...
Novartis concealed data problem before seeking approval for USD 2.1 million gene therapy Zolgensma: USFDA Medical Dialogues Bureau8 Aug 2019 9:15 AM ISTThe FDA said in a statement that AveXis Inc., the Novartis AG subsidiary that manufactures Zolgensma, told the agency five weeks after the approval of...
Novartis, Gilead costly cancer therapies Yescarta, Kymriah losing patients to experimental treatments Medical Dialogues Bureau3 Aug 2019 9:15 AM ISTBoth Gilead's Yescarta and Novartis's Kymriah - which are part of a class of therapies known in the medical field as "CAR-T" - were approved in 2017....
Novartis Expiry of Patent for Blockbuster Vildagliptin to Clear Way for Competitors Farhat Nasim30 July 2019 2:08 PM ISTNew Delhi: The patent protection of blockbuster anti-diabetic drug Vildagliptin manufactured by the Swiss drugmaker, Novartis, will soon expire on...
Novartis CEO Vas Narasimhan vows not to sell Sandoz generics unit Medical Dialogues Bureau29 July 2019 9:17 AM ISTNovartis is revamping Sandoz, a process Narasimhan has previously said will take roughly the next year and a half. He has already sold a generic U.S....
